HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Michael C Wei Selected Research

2- (3- (2- (1- isopropyl- 3- methyl- 1H- 1,2- 4- triazol- 5- yl)- 5,6- dihydrobenzo(f)imidazo(1,2- d)(1,4)oxazepin- 9- yl)- 1H- pyrazol- 1- yl)- 2- methylpropanamide

1/2021Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers.
11/2019A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer.
1/2018Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Michael C Wei Research Topics

Disease

6Neoplasms (Cancer)
01/2021 - 10/2004
6Leukemia
10/2019 - 11/2013
5Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
11/2018 - 11/2013
2Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
04/2022 - 01/2022
2Breast Neoplasms (Breast Cancer)
11/2019 - 01/2018
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
11/2019
1Genetic Translocation (Chromosomal Translocation)
10/2019
1Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
10/2019
1Disease Progression
01/2018
1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Leukemia, Pre B Cell)
12/2016
1Philadelphia Chromosome
12/2014
1Cataract (Cataracts)
04/2013
1Bacteremia
08/2009
1Acute Liver Failure (Fulminant Hepatic Failure)
03/2008

Drug/Important Bio-Agent (IBA)

32- (3- (2- (1- isopropyl- 3- methyl- 1H- 1,2- 4- triazol- 5- yl)- 5,6- dihydrobenzo(f)imidazo(1,2- d)(1,4)oxazepin- 9- yl)- 1H- pyrazol- 1- yl)- 2- methylpropanamideIBA
01/2021 - 01/2018
2Alkylating AgentsIBA
04/2022 - 01/2022
2Proteins (Proteins, Gene)FDA Link
10/2019 - 12/2016
2Dasatinib (BMS 354825)FDA Link
11/2018 - 12/2016
2Transcription Factors (Transcription Factor)IBA
01/2018 - 12/2014
2EnzymesIBA
12/2016 - 12/2014
1DNA (Deoxyribonucleic Acid)IBA
01/2021
1Protein Isoforms (Isoforms)IBA
01/2021
1Docetaxel (Taxotere)FDA Link
11/2019
1taxaneIBA
11/2019
1Paclitaxel (Taxol)FDA LinkGeneric
11/2019
1Tyrosine Kinase InhibitorsIBA
11/2018
1Fulvestrant (Faslodex)FDA Link
01/2018
1Histones (Histone)IBA
01/2018
1Hormones (Hormone)IBA
01/2018
1Histone-Lysine N-MethyltransferaseIBA
01/2018
1src-Family KinasesIBA
12/2016
1Pre-B Cell ReceptorsIBA
12/2016
1histone H3 trimethyl Lys4IBA
08/2015
1Phosphotransferases (Kinase)IBA
12/2014
1Surface Antigens (Surface Antigen)IBA
12/2014
1Pharmaceutical PreparationsIBA
12/2014
1STF-118804IBA
11/2013

Therapy/Procedure

6Therapeutics
04/2022 - 10/2004
2Transplantation
10/2019 - 12/2016
1Duration of Therapy
01/2018
1Lasers (Laser)
04/2013
1Catheters
08/2009
1Liver Transplantation
03/2008
1Drug Therapy (Chemotherapy)
10/2004